Akari Therapeutics (AKTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Akari Therapeutics

    NASDAQ: AKTX · Real-Time Price · USD
    1.10
    -0.01 (-0.90%)
    At close: Sep 25, 2025, 3:59 PM

    Akari Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 14K 4K 3.71K 4.13K
    Gross Profit
    		 -14K -4K -3.71K -4.13K
    Operating Income
    		 -21.64M -16.81M -23.09M -17.21M
    Interest Income
    		 8K 82K 45.94K 10.6K
    Pretax Income
    		 -19.79M -10.01M -17.75M -17.42M
    Net Income
    		 -19.79M -10.01M -6.97M -17.61M
    Selling & General & Admin
    		 9.66M 11.36M 13.53M 8.08M
    Research & Development
    		 6.98M 12.13M 9.56M 9.13M
    Other Expenses
    		 -14K -6.68M 802.79K -27.48K
    Operating Expenses
    		 16.63M 16.81M 23.89M 17.21M
    Interest Expense
    		 -244K n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 21.64M 16.81M 23.09M 17.21M
    Income Tax Expense
    		 n/a n/a -10.78M 182.62K
    Shares Outstanding (Basic)
    		 11.94K 4.89K 3.12K 2.15K
    Shares Outstanding (Diluted)
    		 11.94K 4.89K 3.12K 2.15K
    EPS (Basic)
    		 -1.66K -200 -220 -820
    EPS (Diluted)
    		 -1.66K -200 -220 -820
    EBITDA
    		 -21.64M -16.8M -23.08M -17.21M
    EBIT
    		 -20.04M -16.81M -23.09M -17.21M
    Depreciation & Amortization
    		 -1.61M 4K 3.71K 4.13K

    Add to Watchlist